Effect of Gelonin Immunoconjugate with Monoclonal Antibody MSN‐1 to Endometrial Adenocarcinoma on Antigen‐producing Tumor Cells in vivo

Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN‐1 (IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 1998-05, Vol.89 (5), p.583-588
Main Authors: Kaneta, Yoshibumi, Tsukazaki, Katsumi, Kubushiro, Kaneyuki, Aoki, Rui, Sakayori, Motoko, Ueda, Masakazu, Nozawa, Shiro
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - therapy
Animals
Antibodies, Monoclonal - therapeutic use
Antineoplastic agents
Antineoplastic Agents, Phytogenic - therapeutic use
Biological and medical sciences
Cell Death
Cytotoxicity
Endometrial adenocarcinoma
Endometrial Neoplasms - therapy
Endometrium
Female
Gelonin
Immunoconjugates - therapeutic use
Immunoglobulin M
Immunotherapy
in vivo
Key words
Medical sciences
Mice
Mice, Nude
Missile therapy
Monoclonal antibodies
MSN‐1
Organ Size
Pharmacology. Drug treatments
Plant Proteins - administration & dosage
Plant Proteins - therapeutic use
Propionic acid
Ribosome Inactivating Proteins, Type 1
Therapeutic applications
Tumor cells
Tumor Cells, Cultured
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN‐1 (IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant hemitoxin named gelonin via a disulfide bond using N‐succinimidyl‐3‐(2‐pyridyldithio)propionate and 2‐iminothiolane, and examined its selective cytotoxicity in athymic mice. The reductions in resected weights of target tumor cells, at the local site of MSN‐1‐gelonin immunoconjugate treatment, were 96% with local administration and 75% with caudal vein administration, as compared with the untreated group. There was no weight loss in treated mice. Our results suggest that this MSN‐1‐gelonin immunoconjugate has potential clinical applications in the treatment of endometrial adenocarcinomas.
ISSN:0910-5050
1347-9032
1349-7006
1876-4673
DOI:10.1111/j.1349-7006.1998.tb03301.x